Voriconazole increases while itraconazole decreases plasma meloxicam concentrations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 587-592

  Hynninen, V V ^a,b   Olkkola, K T ^b   Bertilsson, L ^c   Kurkinen, K J ^d   Korhonen, T ^a   Neuvonen, P J ^d   Laine, K ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; MELOXICAM; THROMBOXANE B2; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VISUAL DISORDER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; BLOOD COAGULATION; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GENOTYPE; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE; PROTEIN BINDING; PYRIMIDINES; THIAZINES; THIAZOLES; THROMBOXANE B2; TRIAZOLES; YOUNG ADULT;

EID: 59749094817     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00530-08     Document Type: Article

References (29)

1. Backman, J. T., K. T. Kivisto, K. T. Olkkola, and P. J. Neuvonen. 1998. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54:53-58.
2. Blain, H., C. Boileau, F. Lapicque, E. Nedelec, D. Loeuille, C. Guillaume, A. Gaucher, C. Jeandel, P. Netter, and J. Y. Jouzeau. 2002. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Clin. Pharmacol. 53:255-265.
3. Brideau, C., S. Kargman, S. Liu, A. L. Dallob, E. W. Ehrich, I. W. Rodger, and C. C. Chan. 1996. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45:68-74.
4. Busch, U., G. Heinzel, and H. Narjes. 1995. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur. J. Clin. Pharmacol. 48:269-272.
5. Busch, U., G. Heinzel, H. Narjes, and G. Nehmiz. 1996. Interaction of meloxicam with cimetidine, Maalox, or aspirin. J. Clin. Pharmacol. 36:79-84.
6. Chesne, C., C. Guyomard, A. Guillouzo, J. Schmid, E. Ludwig, and T. Sauter. 1998. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 28:1-13.
7. de Meijer, A., H. Vollaard, M. de Metz, B. Verbruggen, C. Thomas, and I. Novakova. 1999. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin. Pharmacol. Ther. 66:425-430.
8. Engelhardt, G., R. Bogel, C. Schnitzer, and R. Utzmann. 1996. Meloxicam: influence on arachidonic acid metabolism. 1. In vitro findings. Biochem. Pharmacol. 51:21-28.
9. Gage, R., and D. A. Stopher. 1998. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. 17:1449-1453.
10. Gates, B. J., T. T. Nguyen, S. M. Setter, and N. M. Davies. 2005. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin. Pharmacother. 6:2117-2140.
11. Gubbins, P. O., B. J. Gurley, and J. Bowman. 1998. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J. Pharm. Biomed. Anal. 16:1005-1012.
12. Hardin, T. C., J. R. Graybill, R. Fetchick, R. Woestenborghs, M. G. Rinaldi, and J. G. Kuhn. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32:1310-1313.
13. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
14. Ji, H. Y., H. W. Lee, Y. H. Kim, D. W. Jeong, and H. S. Lee. 2005. Simultaneous determination of piroxicam, meloxicam, and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 826:214-219.
15. Kaukonen, K. M., K. T. Olkkola, and P. J. Neuvonen. 1998. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 53:445-449.
16. Muller, F. O., R. Schall, A. C. de Vaal, G. Groenewoud, H. K. Hundt, and M. V. Middle. 1995. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur. J. Clin. Pharmacol. 48:247-251.
17. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28:1805-1808.
18. Olkkola, K. T., J. Ahonen, and P. J. Neuvonen. 1996. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82:511-516.
19. Panara, M. R., G. Renda, M. G. Sciulli, G. Santini, M. Di Giamberardino, M. T. Rotondo, S. Tacconelli, F. Seta, C. Patrono, and P. Patrignani. 1999. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacol. Exp. Ther. 290:276-280.
20. Purkins, L., N. Wood, K. Greenhalgh, M. D. Eve, S. D. Oliver, and D. Nichols. 2003. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl. 1):2-9.
21. Purkins, L., N. Wood, D. Kleinermans, and D. Nichols. 2003. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. 56(Suppl. 1):24-29.
22. Rinder, H. M., J. B. Tracey, M. Souhrada, C. Wang, R. P. Gagnier, and C. C. Wood. 2002. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J. Clin. Pharmacol. 42:881-886.
23. Saari, T. I., K. Laine, K. Leino, M. Valtonen, P. J. Neuvonen, and K. T. Olkkola. 2006. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin. Pharmacol. Ther. 79:362-370.
24. Schmid, J., U. Busch, G. Heinzel, G. Bozler, S. Kaschke, and M. Kummer. 1995. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dispos. 23:1206-1213.
25. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.
26. Turck, D., U. Busch, G. Heinzel, and H. Narjes. 1997. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 47:253-258.
27. Venkatakrishnan, K., L. L. von Moltke, and D. J. Greenblatt. 2000. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38:111-180.
28. von Moltke, L. L., D. J. Greenblatt, J. Schmider, S. X. Duan, C. E. Wright, J. S. Harmatz, and R. I. Shader. 1996. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36:783-791.
29. Yasar, U., S. Lundgren, E. Eliasson, A. Bennet, B. Wiman, U. de Faire, and A. Rane. 2002. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299:25-28.